Kenneth Taylor, MD
Cardiovascular Disease · Atlanta, GANPI 1053316109
Payments from drug & device makers
Across 77 payments — averaging $326.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$24K
- Novartis$460
- Pfizer$177
- Inspire Medical Systems, Inc.$81
- Amgen$41
- Alnylam Pharmaceuticals Inc.$29
- plus $143 from 8 others
What the payments were for
- Consulting fees$1,2005%
- Speaking & faculty fees$22,86091%
- Food & beverage$1,1144%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 27 | $24,246 |
| Novartis | 28 | $460 |
| Pfizer | 8 | $177 |
| Inspire Medical Systems, Inc. | 2 | $81 |
| Amgen | 3 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Philips North America LLC | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Bayer | 1 | $22 |
| Abbott | 1 | $17 |
| Merck | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Medtronic | 1 | $14 |
| Boston Scientific | 1 | $11 |
How this compares
$25,177 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $172,024 |
| JardianceEmpagliflozin | 113 | $121,713 |
| EntrestoSacubitril/Valsartan | 65 | $89,395 |
| XareltoRivaroxaban | 22 | $27,266 |
| Ezetimibe | 315 | $6,124 |
| Rosuvastatin Calcium | 297 | $4,770 |
| Metoprolol Succinate | 322 | $3,932 |
| Nebivolol Hcl | 40 | $2,843 |
| Atorvastatin Calcium | 219 | $1,998 |
| Amlodipine Besylate | 166 | $1,203 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 49 | $941 |
| Verapamil ErVerapamil Hcl | 22 | $812 |
| Losartan Potassium | 94 | $810 |
| Nitroglycerin | 42 | $687 |
| Carvedilol | 72 | $551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $177 | $172,024169 claims |
| Boehringer IngelheimJardiance | $23 | $121,713113 claims |
| NovartisEntresto | $460 | $89,39565 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Atlanta
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Bobby KhanAtlanta$1.7M
- Michael MorrisAtlanta$1.1M
- Modele OgunniyiAtlanta$1M
- Joseph MillerAtlanta$771K
- Mani VannanAtlanta$716K
- Gautam KumarAtlanta$639K
- Melvin EcholsAtlanta$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.